Literature DB >> 22704409

Clinical epidemiology survey of the traditional Chinese medicine etiology and syndrome differentiation of coronary artery disease: study protocol of a multicenter trial.

Ying-fei Bi1, Jing-yuan Mao, Xian-liang Wang, Ya-zhu Hou, Yi-zhu Lu, Shan Bin Soh, Bo-li Zhang.   

Abstract

BACKGROUND: Coronary artery disease (CAD), a common disease with high incidence and mortality rate, has seriously threatened the health and life of the public. Traditional Chinese medicine (TCM) has an important role in the prevention and treatment of this disease. Through clinical epidemiological survey, a deeper understanding of TCM etiology and syndrome characteristics in CAD would further improve clinical efficacy in the treatment of this disease. METHODS/
DESIGN: The preliminary clinical questionnaire for TCM etiology and syndrome differentiation in CAD was designed after literature reviews and analysis. Through a series of clinical pre-surveys, expert consultation and demonstration, the formal TCM clinical epidemiology questionnaire on the etiology and syndrome differentiation in CAD was finalized, after which, the study protocol, inclusive and exclusive criteria and related quality control measures were prepared. The multiregional clinical epidemiological survey with more than 5000 participants with CAD will be carried out in 41 TCM hospitals of China for investigating the TCM etiology and syndrome differentiation of CAD. DISCUSSION: Multiregion large sample size clinical epidemiology survey on TCM etiology and syndrome differentiation in CAD will provide further evidence in preventing CAD and improving the standardization process of syndrome research. TRIAL REGISTRATION: This study protocol was registered at the Chinese Clinical Trial Registry on November 27, 2011 in both Chinese and English editions and the registration number is ChiCTR-ECS-11001728.

Entities:  

Mesh:

Year:  2012        PMID: 22704409     DOI: 10.3736/jcim20120604

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  4 in total

1.  Intermedin attenuates myocardial infarction through activation of autophagy in a rat model of ischemic heart failure via both cAMP and MAPK/ERK1/2 pathways.

Authors:  Peng Wei; Xiang-Jun Yang; Qiang Fu; Bing Han; Lin Ling; Jie Bai; Bin Zong; Chun-Ying Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Deregulation of microRNA-193b affects the proliferation of liver cancer via myeloid cell leukemia-1.

Authors:  Wenjun Yin; Yuehua Nie; Lingying Chen; Quipping Wang; Shuangquan Liu; Xiusheng He; Wenjun Wang
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

3.  Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial.

Authors:  Pan-Pan Tian; Jun Li; Jian Gao; Ying Li
Journal:  BMJ Open       Date:  2018-02-14       Impact factor: 2.692

4.  Observational Study of the Association between TCM Zheng and Types of Coronary Artery Stenosis: Protocol of a Multicenter Case Series Study.

Authors:  Chao Liu; Guang Chen; Dan Liu; Shaoping Nie; Xiao Wang; Xinsheng Huang; Haitao Li; Yi Li; Shihua Luo; Guoan Zhao; Fei Lin; Haoqiang He; Jun Li; Yanwei Xing; Zhenpeng Zhang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-04       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.